Almac is doubling its analytical capacity at its North American headquarters in Souderton, Penn., increasing the number of employed scientists from 10 to 20.
The 240,000-square-foot facility, built on a 40-acre site, delivers full-service, integrated clinical packaging, drug supply management and technology solutions to pharmaceutical and biotech clients. The facility boasts state-of-the-art analytical labs, supplementing facilities in the U.K.
The additional lab investment will offer new support in the form of polymorph and salt screening, solid form development and the latest bathless dissolution apparatus for rapid and efficient comparative dissolution studies. The last will provide maximum flexibility for developing, validating and running assay, dissolution and stability methods, further complementing the large capacity stability chambers which provide all the required ICH stability conditions.
In addition, the lab will continue to provide support for clinical packaging operations and stand-alone analytical services.
The analytical facility complements Almac’s specialty capabilities, including biocatalysis, radiolabelling, and peptide and protein synthesis. These services are all part of Almac’s comprehensive drug development services, including API and drug product development and GMP manufacture.